Low dose ultra-slow infusion thrombolytic therapy (ldusitt) as an alternative option in a covid-19 patient with free-floating right atrial thrombus: a case report and review of literature

HIGHLIGHTS

  • who: Mahsa Mahjani from the University of Medical Sciences, Tehran, Iran have published the paper: Low dose ultra-slow infusion thrombolytic therapy (LDUSITT) as an alternative option in a COVID-19 patient with free-floating right atrial thrombus: a case report and review of literature, in the Journal: (JOURNAL)

SUMMARY

    Thromboembolic events are a major complication in COVID-19 patients. The widespread thrombosis events in COVID-19 patients despite prophylactic or fully therapeutic anticoagulation raise concerns regarding thrombotic adverse events specially in severely ill patients. Operative thrombectomy with exploration in right chambers is . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?